Clearside Biomedical Q1 net loss narrows to $8.2M; FDA agrees on Phase 3 plan for CLS-AX in wet AMD

Clearside Biomedical, Inc.

2025-Q1 EPS reported -$0.11 vs consensus -$1.66 ▲ beat (+93.4%)

Net loss $8.2M ($0.11/sh) vs $11.8M ($0.17) YoY; license revenue $2.3M (up from $0.2M) on Arctic Vision milestone.
Successful End-of-Phase 2 FDA meeting; alignment on Phase 3 design for CLS-AX targeting 3-6 month flexible dosing in wet AMD.
Partner Arctic Vision: ARCATUS approved in Australia and Singapore; NDA accepted for review in China for uveitic macular edema.
Partner BioCryst authorized to start clinical trial for avoralstat in DME using Clearside's SCS Microinjector; initial data expected in 2025.
Cash $13.6M at March 31, expected to fund operations into Q4 2025.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-071386
form_type: 8-K
ticker: CLSDQ
cik: 0001539029
company_name: Clearside Biomedical, Inc.
filed_at: 2025-05-14T23:59:59+00:00
discovered_at: 2026-05-14T18:02:48.695273+00:00
generated_at: 2026-05-21T08:39:33.412212+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-071386
json_url: https://secwatch.observer/filing/0000950170-25-071386.json
markdown_url: https://secwatch.observer/filing/0000950170-25-071386.md
text_url: https://secwatch.observer/filing/0000950170-25-071386.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017025071386/0000950170-25-071386-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017025071386/clsd-20250514.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0000950170-25-071386

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.